Attenuation of haemodynamic, metabolic and energy expenditure responses to isoproterenol in patients with hypertension

Journal of Hypertension

Volumn 22, Issue 10, 2004, Pages 1999-2006

  Valentini, Mariaconsuelo ^a   Julius, Stevo ^a,d   Palatini, Paolo ^b   Brook, Robert D ^a   Bard, Robert L ^a   Bisognano, John D ^c   Kaciroti, Niko ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF ROCHESTER   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Adrenergic; Down regulation; Hypertension; Obesity; Sympathetic nervous system; receptors

Indexed keywords

BETA ADRENERGIC RECEPTOR; GLUCOSE; ISOPRENALINE; NORADRENALIN; PHOSPHATE; SODIUM CHLORIDE;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; ENERGY EXPENDITURE; FEMALE; HEART RATE; HEMODYNAMICS; HUMAN; HYPERTENSION; MALE; METABOLISM; NORADRENALIN BLOOD LEVEL; OBESITY; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SYMPATHETIC TONE; THERMOGENESIS; WEIGHT GAIN;

EID: 5044231782     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200410000-00024     Document Type: Article

References (30)

1. Esler M, Julius S, Zweifler A, Randall O, Harburg E, Gardiner H, et al. Mild high-renin essential hypertension. Neurogenic human hypertension? N Engl J Med 1977; 296:405-411.
2. Goldstein DS. Plasma catecholamines and essential hypertension: an analytical review. Hypertension 1983; 5:86-99.
3. Julius S, Krause L, Schork NJ, Mejia AD, Jones KA, van de Ven C, et al. Hyperkinetic borderline hypertension in Tecumseh, Michigan. J Hypertens 1991; 9:77-84.
4. Kannel WB, Brand N, Skinner JJ Jr, Dawber TR, McNamara PM. The relation of adiposity to blood pressure and development of hypertension. Ann Intern Med 1967; 67:48-59.
5. Julius S, Valentini M, Palatini P. Overweight and hypertension. A 2-way street? Hypertension 2000; 35:807-813.
6. Masuo K, Mikami H, Ogihara T, Tuck ML. Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population. Am J Hypertens 1997; 10:77-83.
7. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003; 42:474-480.
8. MacDonald IA, Bennet T, Fellows IW. Catecholamines and the control of metabolism in man. Clin Sci 1985; 68:613-619.
9. Welle S, Schwartz RG, Statt M. Reduced metabolic rate during β-adrenergic blockade in humans. Metabolism 1991; 40:619-622.
10. Julius S, Randall OS, Esler MD, Kashima T, Ellis C, Bennett J. Altered cardiac responsiveness and regulation in the normal cardiac output type of borderline hypertension. Circ Res 1975; 36/37 (suppl I):1199-1207.
11. Kjeldsen SE, Zweifler AJ, Petrin J, Weder AB, Julius S. Sympathetic nervous system involvement in essential hypertension: increased platelet noradrenaline coincides with decreased β-adrenoceptor responsiveness. Blood Press 1994; 3:164-171.
12. Weir JB. New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol Lond 1949; 55:14-21.
13. Riggin RM, Kissinger PT. Determination of catecholamines in urine by reverse-phase liquid chromatography with electrochemical detection. Annal Chem 1977; 49:2109-2111.
14. Verbeke G. Longitudinal data analysis. In: Verbeke G, Molenberghs G (editors): Linear mixed models in practice: A SAS-oriented overview, no. 126. Lecture notes in statistics. New York: Springer-Verlag; 1997, pp. 63-153.
15. Feldman RD. Defective venous beta-adrenergic response in borderline hypertensive subjects is corrected by a low sodium diet. J Clin Invest 1990; 85:647-652.
16. Stein CM, Nelson R, Deegan R, He H, Wood M, Wood AJJ. Forearm beta adrenergic receptor-mediated vasodilatation is impaired, without alteration of forearm norepinephrine spillover, in borderline hypertension. J Clin Invest 1995; 96:579-585.
17. Landsberg L. Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why). J Hypertens 2001; 19:523-528.
18. Arner P. Catecholamine-induced lipolysis in obesity. Int J Obes 1999; 23 (suppl 1):10-13.
19. Schwartz RS, Jaeger LF, Silberstein S, Veith RC. Sympathetic nervous system activity and the thermic effect of feeding in men. Int J Obes 1987; 11:141-149.
20. Arch JRS. β-3 Adrenoceptor agonists: potentials, pitfalls and progress. Eur J Pharmacol 2002; 440:99-107.
21. Liu YL, Toubro S, Astrup A, Stock MJ. Contribution of β-3 adrenoceptor activation to epinephrine-induced thermogenesis in humans. Int J Obes 1995; 19:678-685.
22. Nantel F, Bonin H, Emorine V, Zilberfarb V, Strosberg AD, Bouvier M, et al. The human β3-adrenergic receptor is resistant to short-term agonist-promoted desensitization. Mol Pharmacol 1993; 43:548-555.
23. Jockers R, Issad T, Zilberfarb V, de Coppet P, Marullo S, Strosberg AD. Desensitization of the beta-adrenergic response in human brown adipocytes. Endocrinology 1998; 139:2676-2684.
24. Scheidegger K, O'Connell M, Robbins DC, Danforth E Jr. Effects of chronic beta-receptor stimulation on sympathetic nervous system activity, energy expenditure, and thyroid hormones. J Clin Endocrinol Metab 1984; 58:895-903.
25. Weyer C, Tataranni PA, Snitker S, Danforth E Jr, Ravussin E. Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans. Diabetes 1998; 47:1555-1561.
26. Mathvink RJ, Tolmans JS, Chitty D, Candelore MR, Cascieri MA, Colwell LF Jr, et al. Discovery of a potent, orally bioavailable beta(3) adrenergic receptor agonist (R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl] amino] ethyl]-phenyl]-4-[4-[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide. J Med Chem 2000; 43:3832-3836.
27. Bloom JD, Dutia MD, Johnson BD, Wissner A, Burns MG, Largis EE, et al. Disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2- hydroxyethyl]-amino] propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316 243). A potent beta-adrenergic agonist virtually specific for beta 3 receptors. A promising antidiabetic and antiobesity agent. J Med Chem 1992; 35:3081-3084.
28. Van Baak MA, Hul GB, Toubro S. Acute effect of L-796568, a novel beta 3-adrenergic receptor agonist, on energy expenditure in obese men. Clin Pharmacol Ther 2002; 71:272-279.
29. Buemann B, Toubro S, Astrup A. Effects of the two (β3 -agonists, ZD7114 and ZD2079 on 24 hour energy expenditure and respiratory quotient in obese subjects. Int J Obes 2000; 24:1553-1560.
30. Bertel O, Buhler FR, Kiowski W, Lutold BE. Decreased beta-adrenoreceptor responsiveness as related to age, blood pressure, and plasma catecholamines in patients with essential hypertension. Hypertension 1980; 2:130-138.